Early proteomic analysis may allow noninvasive identification of hepatitis C response to treatment with pegylated interferon α-2b and ribavirin.

@article{Devitt2011EarlyPA,
  title={Early proteomic analysis may allow noninvasive identification of hepatitis C response to treatment with pegylated interferon α-2b and ribavirin.},
  author={Emma J Devitt and Karen A Power and Matthew W. Lawless and John A. Browne and Peadar O Gaora and William M. Gallagher and John Crowe},
  journal={European journal of gastroenterology & hepatology},
  year={2011},
  volume={23 2},
  pages={177-83}
}
BACKGROUND AND AIM Chronic hepatitis C virus (HCV) infection represents a significant disease burden worldwide. Approximately 170 million people are chronically infected. HCV can lead to liver fibrosis, cirrhosis and hepatocellular carcinoma. Current standard treatment with pegylated interferon and ribavirin is suboptimal and up to 60% of patients fail to… CONTINUE READING